BIRC5 and cancer: Based on the association between survivin expression and platinum resistance in other cancer types [11], as well as on the clinical activity of platinum chemotherapy in some patients with AR-independent mCRPC [4], we explored the association between survivin expression and clinical outcomes in mCRPC patients and evaluated the efficacy of YM155—both as monotherapy and in combination with carboplatin—in AR-negative mCRPC cell lines.